Bailes J S
Clinical Practice Committee, American Society of Clinical Oncology, McAllen, TX.
Semin Oncol. 1994 Aug;21(4 Suppl 7):118-22.
Third-party payer reimbursement policies have undergone significant changes in recent years and will probably continue to do so as the nation's health care system is reformed. These changes will have important implications for oncologists, similar to those that have arisen as a result of Medicare's payment system changing from one of "reasonable charges" to a fixed-fee schedule. The likely growth of managed competition as part of health care reform may prove to be disadvantageous to the oncologist without laws or rules guaranteeing cancer patients the right to treatment by a specialist and to tertiary care. Other areas of importance that will probably be affected include reimbursement of patient care costs associated with clinical trials and of drug costs when the drug is used for off-label indications.
近年来，第三方支付方的报销政策发生了重大变化，随着国家医疗保健系统的改革，这种变化可能还会持续下去。这些变化将对肿瘤学家产生重要影响，类似于医疗保险支付系统从“合理收费”转变为固定费用表所引发的影响。作为医疗保健改革一部分的管理式竞争的可能增长，若没有法律或规则保障癌症患者接受专科医生治疗和三级护理的权利，可能会对肿瘤学家不利。其他可能受到影响的重要领域包括与临床试验相关的患者护理费用报销，以及药物用于非标签适应症时的药物费用报销。
